Evidence map›Paper›PMID 19959099›Full record

ReviewBest practice & research. Clinical haematology2009

Thrombopoietin in normal and neoplastic stem cell development.

Kenneth Kaushansky, Helen M Ranney

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Best practice & research. Clinical haematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kenneth KaushanskyUniversity of California San Diego Medical Center, San Diego, CA 92103-8811, USA. mal@urmc.rochester.edu
Helen M Ranney
University of California San Diego Medical Center · US

Funding

The Interaction of TPO and Integrins in Hematopoiesis CellsP01HL078784 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GINSBERG, MARK HOWARD · 2005 to 2019
$28.3M
MOLECULAR AND CELLULAR BIOLOGY OF THROMBOPOIETINR01DK049855 · NIDDK · UNIVERSITY OF WASHINGTON · PI GEDDIS, AMY E, KAUSHANSKY, KENNETH · 1995 to 2013
$5.0M
Molecular and Cellular Biology of ThrombopoietinR56DK049855 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GEDDIS, AMY E, KAUSHANSKY, KENNETH · 2008 to 2008
$236k
NHLBI NIH HHS P01 HL078784NIDDK NIH HHS R01 DK049855NIDDK NIH HHS R56 DK049855
6 · The paper itself

Abstract

It has been known for sometime that thrombopoietin acts on megakaryocytic progenitor cells to stimulate platelet production. It has recently been discovered that it also stimulates the self-renewal and expansion of normal murine and human haematopoietic stem cells (HSCs) by acting on its cognate receptor, the product of the myeloproliferative leukaemia (c-MPL) proto-oncogene. The c-MPL receptor may also play an important role in the development of human myeloproliferative disorders, essential thrombocythemia, myelofibrosis and polycythemia vera, cooperating with the dysregulated Janus kinase JAK2V(617)F.

Indexed as

AnimalsHematopoietic Stem CellsHumansMyeloproliferative DisordersProto-Oncogene MasReceptors, ThrombopoietinThrombopoietinMAS1 protein, humanProto-Oncogene MasReceptors, ThrombopoietinThrombopoietin

Identifiers

PMID19959099
PMCPMC2789277
OpenAlexW2143977369

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.